Summary
Charles River Labs reported better-than-expected Q2 2018 results (revenue & earnings) and its management team again raised their full-year guidance.
Charles River not only reported impressive operating results for Q2 2018 but the company also appears to be well-positioned for the future. Additionally, the company's revenue growth prospects appear promising.
I plan to stay long the stock and I may actually add to my position.
This idea was first discussed with members of my private investing community, Going Long With W.G.. To get an exclusive 'first look' at my best ideas, start your free trial today >>
Charles River Laboratories (CRL) has been a top-performer for the R.I.P. Portfolio over the first eight months of 2018, as the stock is up almost 14% on a YTD basis.
CRL data by YChartsThe outperformance for the stock has been great so far this year but, in my opinion, Charles River's latest quarterly operating results, especially from a revenue standpoint, supports the fact that this Contract Research Organization ("CRO") company is well-positioned for 2018 and beyond.

